Cite
HARVARD Citation
Ascierto, P. et al. (n.d.). 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Annals of oncology. p. . [Online].